

**WEDNESDAY, JANUARY 27, 2010**

---

**TOPIC:** FDA Beyond Our Borders: The U.S. FDA Goes Global

**SPEAKER:** Andrew C. von Eschenbach, MD, Senior Advisor, Greenleaf Health LLC

For FY 2010, the Food and Drug Administration (FDA) has requested a total budget of \$3.2 billion, which is \$511 million more than FY 2009 and represents a 19 percent increase — the largest ever in FDA history. Together with the recent appointment of FDA Commissioner Margaret Hamburg, M.D. and her team, there is a new wind blowing at the FDA. What does this mean for the biopharma industry?

At this program, Dr. Andrew C. von Eschenbach, the immediate past FDA commissioner, will discuss the latest regulatory issues, and share his insights, forecasts and recommendations for working with the FDA as well as with the other key regulatory bodies around the world in 2010.

Dr. von Eschenbach has had a distinguished 30-year-long career as a physician, surgeon, oncologist, cancer researcher, medical educator, hospital executive and public servant. He is the only person to have held two of the nation's top healthcare leadership roles - Commissioner of the FDA and Director of the National Cancer Institute (NCI). He resigned as FDA Commissioner in January 2009 after leading the agency since 2005, and he currently provides strategic counsel on regulatory issues at Greenleaf Health LLC.

An internationally renowned cancer specialist and author of more than 200 scientific articles, Dr. von Eschenbach was a founding member of the National Dialogue on Cancer. He has received many professional awards and honors during his career.